**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 67710

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Features of primary pancreatic lymphoma: A bi-institutional review with an emphasis on typical and atypical imaging features**

Segaran N *et al*. PPL typical and atypical features

Nicole Segaran, Kumaresan Sandrasegaran, Catherine Devine, Mindy X Wang, Chintan Shah, Dhakshinamoorthy Ganeshan

**Nicole Segaran, Kumaresan Sandrasegaran,** Department of Radiology, Mayo Clinic Arizona, Phoenix, AZ 85054, United States

**Catherine Devine, Mindy X Wang, Chintan Shah, Dhakshinamoorthy Ganeshan,** Department of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States

**Author contributions:** Segaran N performed data analysis, and wrote the manuscript; Sandrasegaran K, and Ganeshan D designed the research, performed data collection and edited the manuscript; Shah C, and Devine C performed data collection and edited the manuscript; Wang MX contributed to study design and edited the manuscript.

**Corresponding author: Dhakshinamoorthy Ganeshan, MD, Associate Professor,** Department of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, United States. dganeshan@mdanderson.org

**Received:** April 29, 2021

**Revised:** June 29, 2021

**Accepted:** August 10, 2021

**Published online:**

**Abstract**

BACKGROUND

Primary pancreatic lymphoma (PPL) is a rare neoplasm. Being able to distinguish it from other pancreatic malignancies such as pancreatic ductal adenocarcinoma (PDAC) is important for appropriate management. Unlike PDAC, PPL is highly sensitive to chemotherapy and usually does not require surgery. Therefore, being able to identify PPL preoperatively will not only direct physicians towards the correct avenue of treatment, it will also avoid unnecessary surgical intervention.

AIM

To evaluate the typical and atypical multi-phasic computed tomography (CT) imaging features of PPL.

METHODS

A retrospective review was conducted of the clinical, radiological, and pathological records of all subjects with pathologically proven PPL who presented to our institutions between January 2000 and December 2020. Institutional review board approval was obtained for this investigation. The collected data were analyzed for subject demographics, clinical presentation, laboratory values, CT imaging features, and the treatment received. Presence of all CT imaging findings including size, site, morphology and imaging characteristics of PPL such as the presence or absence of nodal, vascular and ductal involvement in these subjects were recorded. Only those subjects who had a pre-treatment multiphasic CT of the abdomen were included in the study.

RESULTS

Twenty-nine cases of PPL were diagnosed between January 2000 and December 2020 (mean age 66 years; 13 males/16 females). All twenty-nine subjects were symptomatic but only 4 of the 29 subjects (14%) had B symptoms. Obstructive jaundice occurred in 24% of subjects. Elevated lactate dehydrogenase was seen in 81% of cases, whereas elevated cancer antigen 19-9 levels were present in only 10% of cases for which levels were recorded. The vast majority (90%) of tumors involved the pancreatic head and uncinate process. Mean tumor size was 7.8 cm (range, 4.0-13.8 cm). PPL presented homogenous hypoenhancement on CT in 72% of cases. Small volume peripancreatic lymphadenopathy was seen in 28% of subjects. Tumors demonstrated encasement of superior mesenteric vessels in 69% of cases but vascular stenosis or occlusion only manifested in 5 out of the twenty-nine individuals (17%). Mild pancreatic duct dilatation was also infrequent and seen in only 17% of cases, whereas common bile duct (CBD) dilation was seen in 41% of subjects. Necrosis occurred in 10% of cases. Size did not impact the prevalence of pancreatic and CBD dilation, necrosis, or mesenteric root infiltration (*P* = 0.525, *P* = 0.294, *P* = 0.543, and *P* = 0.097, respectively). Pancreatic atrophy was not present in any of the subjects.

CONCLUSION

PPL is an uncommon diagnosis best made preoperatively to avoid unnecessary surgery and ensure adequate treatment. In addition to the typical CT findings of PPL, such as homogeneous hypoenhancement, absence of vascular stenosis and occlusion despite encasement, and peripancreatic lymphadenopathy, this study highlighted many less typical findings, including small volume necrosis and pancreatic and bile duct dilation.

**Key Words:** Pancreatic tumors; Primary pancreatic lymphoma; Pancreatic ductal adenocarcinoma; Imaging features; Diagnosis; Computed tomography

Segaran N, Sandrasegaran K, Devine C, Wang MX, Shah C, Ganeshan D. Features of primary pancreatic lymphoma: A bi-institutional review with an emphasis on typical and atypical imaging features. *World J Clin Oncol* 2021; In press

**Core Tip:** Primary pancreatic lymphoma (PPL) is often misdiagnosed as pancreatic adenocarcinoma. This two-center retrospective study of twenty-nine cases emphasized computed tomography (CT) imaging features useful for distinguishing PPL from its mimics. Distinct CT features of PPL, including a large homogenous hypovascular mass, absence of ductal dilation or atrophy, encasement of mesenteric vessels without invasion, and the presence of small volume peripancreatic adenopathy, should alert the clinicians to the potential diagnosis of this rare neoplasm. This study also demonstrated atypical findings such as necrosis and mild pancreatic or biliary ductal dilation should not rule out the diagnosis of PPL.

**INTRODUCTION**

Primary pancreatic lymphoma (PPL) is an extremely rare malignancy, constituting less than 0.5% of pancreatic neoplasms and approximately 1% of all extranodal lymphomas[[1-3](#_ENREF_1)]. The World Health Organization outlines PPL as a mass predominantly located in the pancreas with surrounding lymphatic node involvement[[4](#_ENREF_4)]. In addition to these guidelines, Berhns’ diagnostic criteria require (1) Normal white blood cell count; and (2) Nodal compromise defined within the peripancreatic region, without the presence of palpable superficial lymphadenopathy, mediastinal nodal enlargement, or hepatic and splenic involvement[[5](#_ENREF_5)]. The clinical presentation of PPL often includes abdominal pain, weight loss, nausea and vomiting, and occasionally obstructive jaundice[[4](#_ENREF_4)]. However, these nonspecific characteristics make it difficult to differentiate PPL from other pancreatic cancers, most notably the more common pancreatic ductal adenocarcinoma (PDAC)[[2](#_ENREF_2)]. Furthermore, a paucity of information regarding PPL’s distinctive radiologic findings makes diagnosis with imaging alone challenging[[3](#_ENREF_3)].

Identifying unique preoperative characteristics of PPL so physicians may discriminate between PPL and PDAC early-on is crucial given their mutually exclusive prognoses and managements; while PDAC typically requires surgical intervention, the preferential treatment of PPL is chemotherapy with extensive follow-up due to this disease’s high recurrence rate[[3](#_ENREF_3),[4](#_ENREF_4)]. Therefore, this study aims to evaluate the common and uncommon computed tomography (CT) imaging appearances of PPL, as well as other diagnostic features that may enable definitive diagnosis.

**MATERIALS AND METHODS**

***Study design***

For this retrospective Health Insurance Portability and Accountability Act-compliant study, clinical, radiology, and pathology databases at the University of Texas MD Anderson Cancer Center, Houston, TX and Mayo Clinic, Phoenix, AZ were reviewed. This review searched the period between January 2000 and December 2020 for reports containing the strings “pancreas lymphoma” or “pancreatic lymphoma”. Institutional review board permission was obtained for retrospective assessment of imaging, clinical, and pathologic data with waiver of informed consent from both the institutions involved in this study. The exclusion criteria were: (1) Lymphoma with mediastinal or pelvic adenopathy, bone marrow or hepatosplenic involvement which were considered to be systemic lymphoma and not PPL; (2) Pancreatic tumors suspected to be lymphoma on CT and later biopsy-proven to be another diagnosis on histological examination; (3) Subjects without a pretreatment multiphasic CT examination; and (4) Subjects whose medical records were not available of review.

The derivation of a cohort of 29 subjects is shown in Figure 1. All subjects had biopsy-proven PPL with a mass involving the pancreas. There were 13 males and 16 females with a mean age of 66 years (range, 55-88 years).

***Imaging studies***

Multislice CT scans of the abdomen were obtained in the pre-contrast, arterial, venous, and delayed phases. CT findings such as the size, site, morphology and imaging characteristics of PPL including the presence/absence of nodal, vascular and ductal involvement in these subjects were recorded by two reviewers (DG, KS) with 12 and 18 years of post-fellowship experience in Abdominal Imaging.

***Statistical analysis***

Descriptive statistics were compiled. Differences in sizes of tumors showing atypical findings (*i.e.,* pancreatic and bile duct dilation, mesenteric root infiltration, and tumor necrosis) and those without these findings was performed using the Mann-Whitney test. Frequency of these findings in tumors larger than 10 cm and less than 10 cm was performed with the Chi-Square test. MedCalc 19.3 (MedCalc Software Ltd, Ostend, Belgium) was used for statistical analysis.

**RESULTS**

***Clinical presentation and management***

The clinical presentation of the 29 biopsy-confirmed PPL cases used for imaging and clinical feature evaluation are summarized in Table 1. The most common presenting finding were vague abdominal pain (83%) and nausea and vomiting (31%). Weight loss was present in 21% of cases. Classic “B” symptom (*i.e.* fever, chills, night sweats, weight loss) were only seen in 14% of subjects. Similarly, 14% of cases demonstrated a palpable abdominal mass. Obstructive jaundice appeared in seven out of the twenty-nine subjects (24%).

All twenty-nine subjects underwent chemotherapy; the most common treatment was R-CHOP (given in 72% of cases). R-CVP was administered to 2 subjects (7%). In addition, 5 subjects (17%) underwent radiation therapy.

***Laboratory findings***

Lactate dehydrogenase (LDH) levels were elevated in 17 of the 21 cases for which LDH levels were recorded (81%). Elevated amylase was seen in four out of 11 subjects with recorded values (36%), all of whom presented with bile duct dilation (*n* = 3) or concomitant acute pancreatitis (*n* = 1). Cancer antigen 19-9 (CA 19-9) levels were within normal limits for 18 out of the 20 cases (90%). In the remaining two subjects biliary obstruction was present.

***Imaging features***

The prevalence of imaging findings are given in Table 2. The majority of tumors involved to the head and uncinate process (90%). Only four tumors (14%) occurred in the tail. Mean tumor size was 7.8 cm (range, 4.0-13.8 cm). Typical manifestation included a large (> 5 cm) infiltrative (52%) or focal, well-defined (48%) pancreatic mass, with homogenous hypoenhancement on post-contrast CT (72%) (Figure 2). In 41% of cases there was extension to the duodenum. Mass effect on the adjacent superior mesenteric vessels was seen in sixteen out of the twenty-nine subjects (55%). In addition, the majority of cases (69%) demonstrated encasement of superior mesenteric artery (SMA), superior mesenteric vein (SMV), or both; however, only five subjects (17%) had vascular stenosis or occlusion (Figure 3). In one subject there was active bleeding into the tumor by erosion of a mesenteric artery branch leading to intratumoral hematoma (Figure 4).

Furthermore, pancreatic ductal dilation was absent in 83% of cases; the remaining five subjects demonstrated mild dilation with duct caliber of less than 5 mm (Figures 3 and 5). There was no difference in size of those without and with pancreatic duct dilation (median sizes of 6.9 *vs* 6.8 cm, *P* = 0.525) or in the frequency of pancreatic duct dilation between tumors greater than 10 cm and less than 10 cm (*P* = 0.366). Common bile duct (CBD) dilation was seen in 41% of cases (Figure 3). Tumor size did not differ between those without and with CBD dilation (median sizes of 5.4 *vs* 7.1 cm, *P* = 0.294). There was no difference in frequency of CBD dilation between tumors greater than 10 cm and less than 10 cm (*P* = 0.823)

No cases presented signs of pancreatic atrophy. Peripancreatic lymphadenopathy manifested in eight subjects (28%), five of which included involvement below the renal vein. These nodes all had a short-axis dimension of less than 1.5 cm. Mesenteric root infiltration was seen in 14% of cases (Figures 3 and 5). There was no significant difference in tumor size of those without and with mesenteric root infiltration (median sizes of 6.8 *vs* 12.8 cm, *P* = 0.097), although there was an overall trend for larger tumors to infiltrate the mesentery.

Small foci of low density within tumor less than 10% of volume, and likely to be necrosis, was seen in three cases (10%). These subjects either had acute pancreatitis (*n* = 2) or a duodenal fistula (*n* = 1) (Figure 5). There was no significant difference in size of those without and with necrosis (median sizes of 7.0 *vs* 6.2 cm, *P* = 0.543) or in frequency of necrosis between tumors greater than 10 cm and less than 10 cm (*P* = 0.950).

**DISCUSSION**

In agreement with prior literature, subjects in this study presented with nonspecific abdominal symptoms including vague epigastric pain, nausea and vomiting, weight loss, obstructive jaundice, and a palpable mass, making PPL difficult to distinguish from other pancreatic pathologies based on clinical presentation alone[[4](#_ENREF_4),[6](#_ENREF_6)]. Out of these presentations, the most prevalent in PPL are abdominal pain, nausea and vomiting, and weight loss. The decreased prevalence of obstructive jaundice among PPL cases in comparison to individuals with PDAC could aid differentiating between the two; nevertheless, obstructive jaundice is still a relatively common potential presentation of PPL[[7-10](#_ENREF_7)]. Classic “B” symptoms such as fever, chills, night sweats, and weight loss associated with systemic non-Hodgkin lymphoma are rare in PPL, and only occurred in 4 cases from this study[[4](#_ENREF_4)].

Laboratory values may play a more decisive role in the diagnosis of the PPL. Elevated tumor marker CA 19-9 has been reported in 80% of PDAC cases but is a rare finding of PPL[[4](#_ENREF_4)]. In this study, CA 19-9 was within normal limits for the vast majority of subjects. PPL cases with biliary dilation may be associated with mild elevation of CA 19-9[[11](#_ENREF_11)]. In keeping with this study, elevated amylase has been observed in PPL by other studies and numerous case reports, often due to associated acute pancreatitis or biliary obstruction[[8-10](#_ENREF_8),[12](#_ENREF_12),[13](#_ENREF_13)]. Other useful biomarkers include LDH which is often elevated in non-Hodgkin lymphomas, including PPL, but is less likely to be elevated in other pancreatic neoplasms such as PDAC[[10](#_ENREF_10),[11](#_ENREF_11)].

Despite the potential use of laboratory values to suggest PPL over its mimics, the overall nonspecificity of clinical and laboratory features of PPL emphasizes the importance of imaging. CT is the most common imaging study performed for diagnosis and characterization of pancreatic masses[[9](#_ENREF_9)]. PPL typically manifests as a diffusely infiltrative or focal, well-defined mass with homogenous hypoenhancement on post-contrast CT (Figure 2)[[14](#_ENREF_14),[15](#_ENREF_15)]. In particular, the mass-like appearance can often be mistaken for PDAC. However, one CT feature that suggests PPL over PDAC is encasement of the SMA and/or SMV without narrowing or occlusion; conversely, locally advanced PDAC invades or stenoses these vessels[[4](#_ENREF_4),[6](#_ENREF_6)]. In this study, 69% of cases demonstrated encasement of the SMA, SMV or both, but significantly less had vascular invasion or occlusion.

Lymphadenopathy localized to the peripancreatic region also suggests PPL[[16](#_ENREF_16)]. In particular, the presence of lymphadenopathy below the level of renal hilum may be useful in excluding the diagnosis of PDAC[[9](#_ENREF_9),[17](#_ENREF_17),[18](#_ENREF_18)]. The majority of cases in this study demonstrating lymphadenopathy presented nodal involvement below the renal hilum. In addition, all nodal involvement in this study was less than 1.5 cm in short-axis diameter, which may be useful for differentiating PPL from diffuse lymphoma secondarily involving the pancreas[[19](#_ENREF_19)].

Perhaps the most important findings which indicate PPL rather than PDAC are the absence of pancreatic ductal dilation and pancreatic atrophy; only 17% of subjects in this study showed mild pancreatic ductal dilation (< 5 mm) and no subjects presented pancreatic atrophy (Figures 3 and 5)[[14](#_ENREF_14)]. This is a useful differentiating feature as even small pancreatic adenocarcinoma located in the head of pancreas tends to result in moderate or severe upstream pancreatic ductal dilatation as well as pancreatic atrophy[[4](#_ENREF_4),[6](#_ENREF_6),[20](#_ENREF_20)]. Nevertheless, mild pancreatic duct dilation may still be seen in PPL and should not be used to exclude this diagnosis.

In addition to cases of occasional mild pancreatic ductal dilation, this study has demonstrated multiple atypical features of PPL that have not been widely reported. Interestingly, CBD dilation was seen in a substantial proportion (41%) of subjects. While not widely reported in studies on PPL, Boninsegna *et al*[[21](#_ENREF_21)] found similar results to this study, finding CBD dilation in six out of the fourteen subjects (43%) included in their series.

Ten percent of cases in this cohort showed partial necrosis of the tumor. This finding is contrary to the existing consensus that the presence of necrosis effectively excludes a diagnosis of PPL[[5](#_ENREF_5),[7](#_ENREF_7),[11](#_ENREF_11),[17](#_ENREF_17)]. While most PPL do not present necrosis, this study demonstrates that complications such as concomitant acute pancreatitis or intratumoral fluid collection from a duodenal fistula may lead to this atypical finding (Figure 5).

To our knowledge, infiltration of the mesenteric root by PPL has not been reported by previous studies. This finding was demonstrated in 14% of cases in this study (Figures 3 and 5). As expected, the mesenteric vessels were not thrombosed or occluded; however, in one case stenosis of the SMV was seen (Figure 3). There was active extravasation of blood into the tumor in one subject, likely as a result of tumor erosion of the vessels wall (Figure 4).

There are limitations of this study, including its retrospective design. In addition, PPL is a rare entity, and the combined databases of two major institutions only revealed 29 cases of biopsy-proven PPL with pretreatment multiphase CT. Nevertheless, this study revealed useful data on the differentiating features of PPL, and less typical findings which may occur.

**CONCLUSION**

PPL is a rare tumor, which may be misdiagnosed as PDAC, but differentiation between the two entities is critical in order to avoid unnecessary surgery and associated morbidity and mortality. CT imaging features, combined with clinical presentation and laboratory work, can help improve the diagnosis of PPL. The presence of a large relatively homogenous hypoenhancing mass involving the pancreatic head, absence of pancreatic ductal dilatation or atrophy, lack of vascular stenosis or occlusion despite encasement, and presence of small volume peripancreatic lymphadenopathy are helpful features for diagnosing PPL. However, unusual features such as tumor necrosis and the presence of mild pancreatic or bile duct dilation should not automatically exclude PPL as a potential diagnosis. It is important that clinicians are aware of both typical and atypical findings in order to raise the possibility of PPL without delay in diagnosis.

**ARTICLE HIGHLIGHTS**

***Research background***

Primary pancreatic lymphoma (PPL) is a rare neoplasm. The ability to differentiate PPL from other pancreatic malignancies including pancreatic ductal adenocarcinoma (PDAC) is important for appropriate management. However, the nonspecific characteristics currently associated with PPL and a lack of information regarding PPL’s distinctive imaging features makes diagnosis difficult.

***Research motivation***

Identifying typical and atypical features of PPL on computed tomography (CT), as well as other diagnostic features that may differentiate PPL from its mimics, may enable definitive diagnosis. The discovery of features which distinguish PPL from PDAC early-on is critical to avoid unnecessary surgery.

***Research objectives***

This study aims to evaluate the typical and atypical CT imaging appearances of PPL. In addition, it distinguishes various clinical and laboratory markers which may be useful to identify PPL. An emphasis was placed on differentiating PPL from PDAC, which can be difficult to do using the current characteristics associated with PPL.

***Research methods***

Radiology, clinical, and pathology databases from two institutions were searched for reports between January 2000 and December 2020 containing the strings “pancreas lymphoma” or “pancreatic lymphoma”. The exclusion criteria were: (1) Lymphoma with mediastinal or pelvic adenopathy, bone marrow or hepatosplenic involvement which were considered to be systemic lymphoma and not PPL; (2) Pancreatic tumors suspected to be lymphoma on CT and later biopsy-proven to be another diagnosis on histological examination; (3) Subjects without a pretreatment multiphasic CT examination; and (4) Subjects whose medical records were not available of review. Multislice CT scans of the abdomen were viewed in the pre-contrast, arterial, venous, and delayed phases. The clinical presentation, management, laboratory findings, and imaging features of all included patients (*n* = 29) were evaluated.

***Research results***

All twenty-nine subjects were symptomatic, but only 14% demonstrated B symptoms and 24% demonstrated obstructive jaundice. Lactate dehydrogenase (LDH) levels were elevated in 17 of the 21 cases for which LDH levels were recorded (81%), however cancer antigen 19-9 (CA 19-9) levels were within normal limits for 18 out of the 20 cases for which values were recorded (90%). Pancreatic ductal dilation was absent in 83% of cases and no patients presented pancreatic atrophy. Atypical features of PPL included pancreatic bile duct dilation (17%), common bile duct (CBD) dilation (41%), necrosis (10%), and infiltration of the mesenteric root (14%). Size did not impact the prevalence of pancreatic and CBD dilation, necrosis, or mesenteric root infiltration (*P* = 0.525, *P* = 0.294, *P* = 0.543, and *P* = 0.097, respectively).

***Research conclusions***

The decreased prevalence of obstructive jaundice, elevated CA 19-9 levels, pancreatic ductal dilation, and pancreatic atrophy, as well as the increased elevation of LDH levels, encasement of the small mesenteric artery and/or vein without invasion or stenosis, and lymphadenopathy limited to the peripancreatic region, may be useful for distinguish PPL from its mimics, such as PDAC. However, in addition to the occasional appearance of pancreatic ductal dilation, this study identified multiple atypical features of PPL including the presence of CBD dilation, necrosis, and infiltration of the mesenteric root.

***Research perspectives***

Prospective studies with larger cohorts must be conducted to support the findings of this paper and the potential use of its highlighted imaging and clinical features for definitive diagnosis of PPL. In addition, there is a need for direct comparison of the frequency of these features in PPL *vs* PDAC, to determine how useful they are in differentiating the two entities.

**REFERENCES**

1 **Battula N**, Srinivasan P, Prachalias A, Rela M, Heaton N. Primary pancreatic lymphoma: diagnostic and therapeutic dilemma. *Pancreas* 2006; **33**: 192-194 [PMID: 16868486 DOI: 10.1097/01.mpa.0000227910.63579.15]

2 **Behrns KE**, Sarr MG, Strickler JG. Pancreatic lymphoma: is it a surgical disease? *Pancreas* 1994; **9**: 662-667 [PMID: 7809023]

3 **Boni L**, Benevento A, Dionigi G, Cabrini L, Dionigi R. Primary pancreatic lymphoma. *Surg Endosc* 2002; **16**: 1107-1108 [PMID: 11984658 DOI: 10.1007/s00464-001-4247-1]

4 **Manning MA**, Paal EE, Srivastava A, Mortele KJ. Nonepithelial Neoplasms of the Pancreas, Part 2: Malignant Tumors and Tumors of Uncertain Malignant Potential From the Radiologic Pathology Archives. *Radiographics* 2018; **38**: 1047-1072 [PMID: 29787363 DOI: 10.1148/rg.2018170201]

5 **Dunphy L**, Abbas SH, Al Shoek I, Al-Salti W. Primary Pancreatic lymphoma: a rare clinical entity. *BMJ Case Rep* 2020; **13** [PMID: 31907215 DOI: 10.1136/bcr-2019-231292]

6 **Low G**, Panu A, Millo N, Leen E. Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. *Radiographics* 2011; **31**: 993-1015 [PMID: 21768235 DOI: 10.1148/rg.314105731]

7 **Grossberg AJ**, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. *CA Cancer J Clin* 2020; **70**: 375-403 [PMID: 32683683 DOI: 10.3322/caac.21626]

8 **Shnitser A**, Halegoua-DeMarzio D, Loren DE. Primary Pancreatic Lymphoma Presenting as Acute Pancreatitis. *Gastroenterol Hepatol (N Y)* 2016; **12**: 456-458 [PMID: 27489530]

9 **Merkle EM**, Bender GN, Brambs HJ. Imaging findings in pancreatic lymphoma: differential aspects. *AJR Am J Roentgenol* 2000; **174**: 671-675 [PMID: 10701607 DOI: 10.2214/ajr.174.3.1740671]

10 **Facchinelli D**, Sina S, Boninsegna E, Borin A, Tisi MC, Piazza F, Scapinello G, Maiolo E, Hohaus S, Zamò A, Merli M, Stefani PM, Mellone F, Basso M, Sartori R, Rusconi C, Parisi A, Manfrin E, Krampera M, Ruggeri M, Visco C, Tecchio C. Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome. *Eur J Haematol* 2020; **105**: 468-475 [PMID: 32542880 DOI: 10.1111/ejh.13468]

11 **Rad N**, Khafaf A, Mohammad Alizadeh AH. Primary pancreatic lymphoma: what we need to know. *J Gastrointest Oncol* 2017; **8**: 749-757 [PMID: 28890827 DOI: 10.21037/jgo.2017.06.03]

12 **Abedi SH**, Ahmadzadeh A, Nikmanesh A, Mohammad Alizadeh AH. The role of endoscopic ultrasound in primary pancreatic lymphoma presented with acute pancreatitis: a case report. *JOP* 2014; **15**: 493-496 [PMID: 25262719 DOI: 10.6092/1590-8577/2637]

13 **Li Z**, Zhang S, Vasdani N, Castillo E. Clues for diagnosing primary pancreatic lymphoma. *Case Rep Gastroenterol* 2012; **6**: 438-445 [PMID: 22855659 DOI: 10.1159/000339968]

14 **Anand D**, Lall C, Bhosale P, Ganeshan D, Qayyum A. Current update on primary pancreatic lymphoma. *Abdom Radiol (NY)* 2016; **41**: 347-355 [PMID: 26830418 DOI: 10.1007/s00261-015-0620-8]

15 **Gandhi NS**, Feldman MK, Le O, Morris-Stiff G. Imaging mimics of pancreatic ductal adenocarcinoma. *Abdom Radiol (NY)* 2018; **43**: 273-284 [PMID: 29038855 DOI: 10.1007/s00261-017-1330-1]

16 **Alzerwi NAN**. Primary Pancreatic Lymphoma Masquerading as Carcinoma. *Case Rep Oncol Med* 2020; **2020**: 5160545 [PMID: 32158572 DOI: 10.1155/2020/5160545]

17 **Wallace D**, Dang N, Dhawan M, Kulkarni A. Diagnosis of a patient with primary pancreatic lymphoma. *Gastroenterol Hepatol (N Y)* 2012; **8**: 850-852 [PMID: 24693276]

18 **Saif MW**. Primary pancreatic lymphomas. *JOP* 2006; **7**: 262-273 [PMID: 16685107]

19 **Sandrasegaran K**, Tomasian A, Elsayes KM, Nageswaran H, Shaaban A, Shanbhogue A, Menias CO. Hematologic malignancies of the pancreas. *Abdom Imaging* 2015; **40**: 411-423 [PMID: 25120155 DOI: 10.1007/s00261-014-0217-7]

20 **Elbanna KY**, Jang HJ, Kim TK. Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. *Insights Imaging* 2020; **11**: 58 [PMID: 32335790 DOI: 10.1186/s13244-020-00861-y]

21 **Boninsegna E**, Zamboni GA, Facchinelli D, Triantopoulou C, Gourtsoyianni S, Ambrosetti MC, Veneri D, Ambrosetti A, Pozzi Mucelli R. CT imaging of primary pancreatic lymphoma: experience from three referral centres for pancreatic diseases. *Insights Imaging* 2018; **9**: 17-24 [PMID: 29335928 DOI: 10.1007/s13244-017-0585-y]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved separately by the Institutional Review Boards of University of Texas MD Anderson Cancer and Mayo Clinic of Arizona.

**Informed consent statement:** As this is a retrospective review that involves no diagnostic or therapeutic intervention, as well as no direct patient contact, IRB permission was obtained with waiver of informed consent and waiver of authorization to use and review patient information.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Data sharing statement:** No additional data is available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** April 29, 2021

**First decision:** June 16, 2021

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Caronna R **S-Editor:** Fan JR **L-Editor: P-Editor:**


**Figure Legends**




**Figure 1 Inclusion and exclusion criteria of primary pancreatic lymphoma cohort.** This figure gives the derivation of our cohort of 29 subjects for this study. CT: Computed tomography; PPL: Primary pancreatic lymphoma.




**Figure 2 A 58-year-old male with abdominal pain**. A: Axial computed tomography images demonstrate a large, relatively well-defined focal mass (arrow) involving the uncinate process of the pancreas; B: Axial computed tomography images. The tumor shows homogenous hypoenhancement, without evidence of any necrosis or calcification. The rest of the pancreas is preserved, and there is no pancreatic ductal dilation. Biopsy confirmed diagnosis of primary pancreatic lymphoma.



**Figure 3 A 72-year-old male presenting with abdominal pain and jaundice.** Coronal computed tomography imaging shows hypoenhancing homogenous infiltrative mass (thick arrows, A) infiltrating the mesenteric root. A: There is pancreatic duct dilation (short thin arrow) and common bile duct obstruction (arrowhead); B: There is stenosis of the superior mesenteric vein (long thin arrow) caused by the tumor.



**Figure 4 A 74-year-old female presenting with abdominal pain and nausea.** Axial computed tomography shows mass (thick arrow) encircling an aneurysmal vessel (thin arrow) which is bleeding into the mass, causing hematoma (arrowhead). The tumor was biopsy-proven to be primary pancreatic lymphoma.



**Figure 5 A 62-year-old male presenting with abdominal pain.** Coronal computed tomography images show low-density necrosis (thin short arrow) within tumor (thin long arrow), which infiltrates the mesenteric root without occlusion of mesenteric vessels. There is a collection extending from the third part of the duodenum into tumor (thick arrow) suggesting fistula from probable erosion of duodenal wall. Mild pancreatic duct dilation is seen (arrowhead).

**Table 1 Clinical presentation of primary pancreatic lymphoma**

|  |  |
| --- | --- |
| **Characteristics** | ***n* (%)** |
| Abdominal pain | 24 (83) |
| Nausea and vomiting | 9 (31) |
| Weight loss | 6 (21) |
| Classic “B” symptoms | 4 (14) |
| Palpable mass | 4 (14) |
| Obstructive jaundice | 7 (24) |

**Table 2 Imaging features of primary pancreatic lymphoma**

|  |  |
| --- | --- |
| **Characteristics** | ***n* (%)** |
| Location |  |
| Head | 23 (80) |
| Body | 3 (10) |
| Tail | 4 (14) |
| Uncinate process | 16 (55) |
| Mean size (cm) | 7.8 |
| Infiltrative mass | 15 (52) |
| Focal mass | 14 (48) |
| Homogeneous hypoenhancement | 21 (72) |
| Tumor necrosis | 3 (10) |
| Extension to nuodenum | 12 (41) |
| Mass effect on SMV | 16 (55) |
| Encasement of SMA/SMV | 20 (69) |
| Vascular stenosis/occlusion | 5 (17) |
| Pancreatic ductal dilation | 5 (17) |
| Common bile duct dilation | 12 (41) |
| Pancreatic atrophy | 0 (0) |
| Infiltration of mesenteric root | 4 (14) |
| Peripancreatic lymphadenopathy | 8 (28) |

SMV: Superior mesenteric vein; SMA: Superior mesenteric artery.